News

Harbour BioMed Advances COPD Treatment with New Drug Submission

Harbour BioMed Advances COPD Treatment with New Drug Submission

Harbour BioMed Submits IND Application for Chronic Obstructive Pulmonary Disease

Harbour BioMed, a global player in biopharmaceutical innovation, has taken a significant step in the fight against chronic obstructive pulmonary disease (COPD) by submitting an Investigational New Drug (IND) application. This application was directed to the appropriate regulatory body for their novel therapy, HBM9378/SKB378. This fully human antibody is designed to target thymic stromal lymphopoietin (TSLP), an important factor in the progression of COPD.

The Burden of COPD and Need for Solutions

COPD is a progressive respiratory illness affecting millions globally. It not only leads to severe health complications but also places a heavy strain on healthcare systems worldwide. The disease is associated with increased risks of cardiovascular issues, respiratory failure, and even lung cancer. As the prevalence of COPD continues to rise, there is a pressing demand for innovative therapeutic options that can enhance the quality of life for those affected.

Innovative Approach of HBM9378/SKB378

HBM9378/SKB378 sets itself apart with its fully human sequences, significantly reducing the risk of immunogenicity seen in other TSLP-targeting therapies. This enhancement contributes to better bioavailability and dosing flexibility. According to Dr. Jingsong Wang, the company’s founder and CEO, the unique properties of HBM9378/SKB378 position it as a promising solution for COPD patients, aligning with their diverse needs.

Collaboration in Development

This innovative therapy arises from a co-development strategy between Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Together, they hold global rights to this exciting project. The therapy is built on a sophisticated H2L2 platform, meaning it is generated from two heavy chains and two light chains, which enables it to effectively inhibit the crucial TSLP signaling pathway.

Clinical Trials and Future Prospects

While Harbour BioMed has already completed Phase I trials in China for HBM9378/SKB378 to address moderate-to-severe asthma, the current focus on COPD underlines the commitment to tackling complex respiratory issues. The results from these trials will be pivotal in assessing how effectively this monoclonal antibody can combat COPD.

About Harbour BioMed

Harbour BioMed specializes in the development of novel antibody therapeutics, with a strong spotlight on immunology and oncology. With a robust pipeline fueled by both in-house research and strategic partnerships, the company is dedicated to advancing medical science through innovative therapies. Their proprietary Harbour Mice® technology facilitates the creation of fully human monoclonal antibodies in various formats, ensuring they stay at the forefront of biopharmaceutical advancements.

Frequently Asked Questions

What is HBM9378/SKB378?

HBM9378/SKB378 is a fully human monoclonal antibody targeting TSLP, developed for the treatment of chronic obstructive pulmonary disease (COPD).

Why is COPD a significant health concern?

COPD results in major health complications and increasing healthcare costs. Its progressive nature necessitates effective treatment options to improve patient lives.

What makes HBM9378/SKB378 different from other therapies?

This therapy has a reduced immunogenicity risk and better bioavailability compared to competing treatments, enhancing its therapeutic effectiveness.

How is Harbour BioMed addressing COPD?

By submitting an IND application for HBM9378/SKB378, the company aims to bring a novel therapeutic option to patients suffering from COPD.

What are the future plans for this drug?

The outcomes from ongoing clinical trials will determine the next steps in development and potential approval for HBM9378/SKB378 as a COPD treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ICOGT's Global Expansion Targets Dynamic Markets

Updated Category News Views 3

ICOGT's Ambitious Expansion Plan When the winds of change blow, some build walls, others build wind turbines—and ICOGT is choosing the latter with its ambitious international expansion. September kicks off a new phase for INTERNATIONAL COMPANY OIL & GAS SERVICES & GENERAL TRADING L.L.C, as they lace up for a strategic sprint across key global markets, focusing heavily...

Continue Reading
Union Savings Bank Leverages AI for Strategic Growth

Updated Category News Views 4

USB's Data-Driven Approach Transforms Banking Remember the days of handing out toasters to keep customers? Union Savings Bank (USB) sure doesn't seem to, as it embraces tech-savvy methods to keep its clientele content. Instead, the $3.3 billion community bank based in Danbury, Connecticut, has deployed NGDATA's AI Hub, transforming its approach to reducing customer churn...

Continue Reading
Nauticus Robotics' ROV Activity Boosts Q3 Performance

Updated Category News Views 0

Nauticus Robotics Hits New Stride with ROV Deployments Some days, you're paddling like hell to stay afloat in this market. But for Nauticus Robotics, marking progress amidst turbulent waters, their recent announcement feels like catching a favorable current. Both of Nauticus’ Comanche ROV systems have been deployed for commercial projects, enhancing their third quarter...

Continue Reading
CALLAHEAD's WHITE WASH™: Revamping Portable Restrooms

Updated Category News Views 0

Breaking New Ground in Portable Sanitation Who would've thought a portable restroom could mimic the comforts of a full-blown bathroom? CALLAHEAD™'s WHITE WASH™ just flipped the script on everything we thought we knew about temporary facilities. Forget the standard cramped, subpar porta-potties — this is a game-changer born from 50 years of hard-earned wisdom. A...

Continue Reading
Planet Smoothie Joins Fight Against Childhood Cancer

Updated Category News Views 3

Shaking Up September by Fighting Childhood Cancer Here's a refreshing twist on a complex issue: Planet Smoothie's latest campaign against childhood cancer. They're striding alongside Alex's Lemonade Stand Foundation (ALSF) to drum up support and dollars for a cause that touches many of our hearts. With September in full swing, this partnership isn't just about refreshing,...

Continue Reading
Historic Grayton Beach Home Hits Market at $10.75M

Updated Category News Views 0

A Storied Past Unfurls at 10 Hotz Avenue Down in the sandy stretches of Grayton Beach, Florida, there's a house that's seen more sunsets than most folks have had hot dinners. Enter 10 Hotz Avenue, a place as much a part of the breath and soul of that little beach town as its residents. Ask around, and the old-timers will tell you about its roots in the 1890s, deeply...

Continue Reading
D-Orbit Banks on GomSpace for 2026 Space Ventures

Updated Category News Views 4

Pioneering Paths in Space Logistics Nobody ever said that conquering the final frontier was going to be easy. But D-Orbit, the trailblazer in space logistics, is inking deals like they're playing a cosmic chess game, and GomSpace is the knight they’re moving across the board. Their latest maneuver? GomSpace gets tasked with powering the D-Orbit's missions through 2027,...

Continue Reading
Allegiant Expands Flint-Florida Routes Amid Demand Surge

Updated Category News Views 7

New Routes Set to Shake Up Air Travel Ah, the sweet sound of new routes being announced! Allegiant, that scrappy player on the budget airline stage, just rolled out the red carpet for Flint-area travelers—a move that'll echo loud enough to make competitors sit up straighter. Two nonstop routes taking off from Flint Bishop International Airport (FNT)—to Orlando and...

Continue Reading
Evenflo's Monarch Travel System Redefines Baby Mobility

Updated Category News Views 4

Evenflo's Latest Offering: Monarch Travel System The baby gear market just got a new contender: Evenflo has unveiled its latest innovation—the Monarch™ Travel System. Designed to cater to a family's needs from the infant stage right through toddlerhood, this all-in-one setup claims to package top-notch safety with style and convenience. But what's the real story here?...

Continue Reading
Young Americans' Mixed Feelings on Nation's Direction

Updated Category News Views 0

Youthful Patriotism Meets Stark Realism Picture a generation standing at a crossroads. They've got one foot planted firmly in admiration for the past and the other in unease about the present. American University's latest poll rolls out these insights into the minds of young Americans on the nation's 250th birthday. What we get is a swirl of pride tangled together with...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyst Critiques Oracle's AI Strategy: A Risky Business Model

Updated Category News Views 361

Unpacking Oracle's Controversial AI Strategy A notable technology analyst has raised eyebrows over Oracle Corp.'s recent AI investments, characterizing them as "irresponsible" and based on speculative demand. The analyst noted that unlike the "healthy" business approaches seen at major competitors such as Microsoft Corp., Amazon.com Inc., and Alphabet Inc., Oracle's...

Continue Reading
Innovative Gene Editing Funding Encourages MyoGene's Growth

Updated Category News Views 121

Exciting Developments in Gene Editing Funding Recently, notable advancements have been made in the field of gene therapy, particularly with funding opportunities that promise to change the landscape of treatments for genetic disorders. One such development is the recent commitment by Parent Project Muscular Dystrophy (PPMD), a leading advocate in the research and...

Continue Reading
Class Action Lawsuit Alert Issued for Applied Therapeutics Investors

Updated Category News Views 181

Class Action Lawsuit Alert Issued for Applied Therapeutics Investors Bronstein, Gewirtz & Grossman, LLC, a prominent law firm specializing in class actions, announces that they are representing investors in a newly filed class action lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its officers. If you have incurred substantial losses due to your...

Continue Reading
Real Matters' Annual Meeting Results and Director Elections

Updated Category News Views 151

Real Matters' Annual Meeting Highlights In a significant development for Real Matters Inc., a top provider in network management services for the mortgage and insurance industries, the company recently held its Annual Meeting of Shareholders. This meeting not only addressed various corporate matters but also focused on the election of directors, reflecting the company's...

Continue Reading
Innovative Steps in Cancer Therapy: GlycoNex's New Agreement

Updated Category News Views 198

GlycoNex Partners with Sterling for Advancing Cancer Therapy GlycoNex, Inc. (4168), a pioneering biotechnology company dedicated to developing glycan-directed cancer immunotherapies, has taken a major step forward by announcing a manufacturing agreement with Sterling Pharma Solutions. This collaboration is essential for the clinical trial production of GNX102-ADC, which...

Continue Reading